CG
ADVM

Colony Group’s Adverum Biotechnologies ADVM Stock Holding History

Colony Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-406
Closed -$66K – 841
2015
Q2 		$66K Buy
406
+300
+283% +$101K 0.01% 453
2015
Q1 		$43K Hold
106
– – ﹤0.01% 443
2014
Q4 		$57K Hold
106
– – 0.01% 432
2014
Q3 		$36K Buy
+106
New +$31.5K ﹤0.01% 460

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Colony Group's ADVM Position: Q3 2015 in Review

Colony Group sold out of Adverum Biotechnologies (ADVM) in Q3 2015, closing a stake of 406 shares — an estimated $66K sold.

Colony Group first reported a position in ADVM in Q3 2014 and held it in 4 quarters. The position peaked at $66K in Q2 2015. 92 funds tracked by Wall St. Rank hold ADVM as of Q3 2015.

  • Colony Group reported no remaining Adverum Biotechnologies position as of Q3 2015 after selling out during the quarter.
  • Colony Group sold 406 Adverum Biotechnologies shares in Q3 2015, an estimated $66K.
  • Colony Group first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 4 quarters.
  • Colony Group's Adverum Biotechnologies position peaked at $66K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2015.

Based on Colony Group's 13F filing for Q3 2015, filed 16 Nov 2015.